查詢結果分析
來源資料
相關文獻
- Efficacy and Safety of 20 mg/day Simvastatin in Patients with Renal Impairment and Combined Hyperlipidemia
- 從實證醫學觀點談高血脂症以降血脂藥物治療之爭議
- 高血脂症診斷及合併型高血脂症的治療
- 高血脂症與慢性腎臟病
- 活動量與高血壓及高血脂症的相關探討--金山成年居民的研究
- 外源性膽固醇對缺銅性大白鼠之高血脂症的效應
- 補充綜合抗氧化維生素增強高血脂症抽煙者之抗氧化狀態與減少血漿及低密度脂蛋白之脂質過氧化
- Hyperlipidemia of Normal Pregnancy in Karachi-Pakistan
- 高血脂症與腦血管疾病
- The Effects of Glurenorm on Plasma Glucose and Lipids in Patients with Type 2 Diabetes Mellitus
頁籤選單縮合
題名 | Efficacy and Safety of 20 mg/day Simvastatin in Patients with Renal Impairment and Combined Hyperlipidemia=每天使用20毫克Simvastatin於合併有混合型高脂血症的腎功能異常病人之效果評估 |
---|---|
作 者 | 呂至剛; 黃美美; 白榮貴; 江蔚文; | 書刊名 | 輔仁醫學期刊 |
卷期 | 3:1 民94.03 |
頁次 | 頁43-47 |
分類號 | 418.227 |
關鍵詞 | 降血脂藥物; 高血脂症; 腎功能不足; Simvastatin; Hyperlipidemia; Renal impairment; |
語文 | 英文(English) |
中文摘要 | 目標: 探討以simvastatin 治療合併有混合型高血脂症的腎功能異常病人之效果。方法: 將病人分為兩組,第一組為腎功能異常病人,共有三十位,其中十七位正接受腎臟透析治療,其餘十三位的血清肌肝酸濃度均大於1.3 mg/dl。第二組為腎功能正常的控制組病人,共有二十位,每位血清肌肝酸濃度均小於或等於1.3 mg/dl。兩組病人均接受十六週口服simvastatin 的治療,每天口服一次,劑量為20 毫克。所有病人皆未使用其他的降血脂藥物。結果: 經過十六週治療之後,兩組病人血清中總膽固醇、三酸甘油脂及低密度脂蛋白內膽固醇濃度均顯著的降低。第一組腎功能異常病人的血清中總膽固醇由治療前258 ( 33 降至治療後199 ( 36 mg/dl;三酸甘油脂由383 ( 171 降至273 (107 mg/dl;低密度脂蛋白內膽固醇由150 ( 36 降至101 ( 33 mg/dl (p < 0.01);而第二組腎功能正常的病人的血清中總膽固醇由262 ( 54 降至194 ( 35 mg/dl;三酸甘油脂由485 (201 降至274 ( 210 mg/dl;低密度脂蛋白內膽固醇由118 ( 41 降至101 ( 27 mg/dl (p <0.01)。兩組病人血清中高密度脂蛋白內膽固醇濃度均升高,第一組腎功能異常的病人由39 (11 升高至44( 17mg/dl ( p < 0.05);第二組腎功能正常的病人由38 ( 8 升高至43 (10mg/dl,但統計學上無顯著意義( p= 0.064)。結論:每天以口服一次20 毫克simvastatin治療混合型高血脂症,無論是用在腎功能正常或異常的病人身上,其治療效果及安全性均極為相似。 |
英文摘要 | Background and purpose: We attempted to study the efficacy of 20 mg/day simvastatin as monotherapy in patients with renal impairment combined with hyperlipidemia. Methods: Thirty patients with impaired renal function (serum creatinine of > 1.3 mg/dl, 17 of whom were dialysis patients) were studied. Twenty patients with normal renal function (serum creatinine of £ 1.3 mg/dl) were used as a control group. Once-daily 20 mg simvastatin was administered to all patients for 16 weeks in the absence of other lipid-lowering agents. Results: Serum total cholesterol (TC), triglycerides (TGs), and low-density lipoprotein-cholesterol (LDL-C) in both patient groups significantly decreased after simvastatin treatment (TC from 258±33 to 199±36 mg/dl, TGs from383±171 to 273±107mg/dl, and LDL-Cfrom150±36 to 101±33mg/dl in patients with impaired renal function; TC from 262±54 to 194±35 mg/dl, TG from 485±201 to 274±210 mg/dl, and LDL-C from118±41 to 101±27mg/dl in patientswith normal renal function, all p<0.01). An increase in the serum high-density lipoprotein-cholesterol (HDL-C) also occurred in both patient groups (from 39±11 to 44±17mg/dl, p<0.05 in patients with renal impairment), however, the change in patients with normal renal function was not significant (from 38±8 to 43±10 mg/dl, p=0.064). Conclusion: Monotherapy with 20 mg/day simvastatin has similar safety and effectiveness in patients with normal and those with impaired renal function. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。